- <![CDATA[Perioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBC]]><![CDATA[Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.]]>onclive · 2mo ago↗ source
- <![CDATA[Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer]]><![CDATA[The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer. ]]>onclive · 2mo ago↗ source
- Create Medicines raises $122M to bolster in vivo CAR-T therapies<figure><div><img src="https://imgproxy.divecdn.com/1TNhYQTUI7yObB637nFZIAJqv_C_vHe6B8CqUtpkWHg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTQwMTQ3MDc2LmpwZ…